Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a cancer with dismal prognosis due to resistance to most current therapies. Although immunotherapy has improved the treatment of many solid cancers, pancreatic cancer remains resistant to immunotherapy due to immunosuppressive tumor microenvironmen...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Santeri A. Pakola, Nea Ojala, Tatiana V. Kudling, James H. A. Clubb, Elise Jirovec, Mirte van der Heijden, Victor Arias, Lyna Haybout, Saru Basnet, Susanna Grönberg-Vähä-Koskela, Dafne C. A. Quixabeira, Joao M. Santos, Victor Cervera-Carrascon, Otto Hemminki, Anna Kanerva, Harri Mustonen, Pauli Puolakkainen, Hanna Seppänen, Akseli Hemminki
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Springer 2025-06-01
سلاسل:	Cancer Immunology, Immunotherapy
الموضوعات:	Oncolytic virus Adenovirus, Pancreatic cancer Immunotherapy PD-L1 Checkpoint inhibitor
الوصول للمادة أونلاين:	https://doi.org/10.1007/s00262-025-04072-6
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!